Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
|Articles|February 22, 2021
Pharmacy Times: Week of February 22 Lineup
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
Advertisement
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:
- A video interview with J. David Robertson, the director of University of Missouri Research Reactor (MURR), on how a new collaboration between MURR and Advanced Accelerator Applications International will help to develop a targeted therapy for certain types of cancerous tumors.
- An article from the recent Society for Advancing Business Editing and Writing Healthcare 2021 virtual symposium, which discusses the main challenges surrounding COVID-19 vaccination—increasing vaccine production and delivery. The presentation noted that the faster people are vaccinated, the fewer opportunities there will be for variant versions of COVID-19 to spread and for more variants to emerge.
Advertisement
Related to this article
A retrospective study from Japan found that oncology pharmacist assessment before medical examination was associated with higher rates of complete adverse event resolution in outpatient chemotherapy.
September’s hematology coverage examined a new definition of myeloma cure, patient preferences for treatment delivery, and emerging strategies for deepening responses.
September oncology coverage highlighted new breast and kidney cancer combinations, updated lung cancer labeling, and emerging evidence connecting antibiotic exposure with CAR T-cell outcomes.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
Marie-Claire Seeley, PhD, MNurs, RN, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
A detailed LINKER-MM1 analysis found that cytokine release syndrome (CRS) with linvoseltamab occurred early, was predominantly low grade, and became less frequent with successive step-up and full doses.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-fourths of treated patients.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
September 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds
4
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
5